Again, a second Phase 3 clinical trial demonstrates that dupilumab reduces disease in patients with COPD who have type 2 inflammation.

Published Date: 22 May 2024

According to researchers, patients with type 2 inflammation and chronic obstructive pulmonary disease may soon have access to duplilumab, a new medication that improved patients' conditions quickly and steadily in a pivotal Phase 3 clinical trial.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Charles III, King of Kings, is Cancerous.

2.

Chemo-Free Quadruplet Shows Promise as DLBCL's First Therapy.

3.

Perioperative Anti-PD-1 in Soft-Tissue Sarcoma Boosts Disease-Free Survival

4.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot